Health
Ortho’s VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data – PRNewswire
/PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received…
RARITAN, N.J., March 23, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.
“Communities and laboratories across the United States continue to seek fast, reliable,…
-
Noosa News24 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
General21 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
General20 hours agoTwo men involved in fatal helicopter accident charged over stealing crocodile eggs from Kakadu National Park
-
Business22 hours agoMacquarie predicts more than 40% upside for this ASX 200 stock